Lingrui Pharma(600285) 搜狐财经·2025-04-25 12:47Core Viewpoint - Lingrui Pharmaceutical announced a cash dividend plan for the fiscal year 2024, proposing a distribution of 9 yuan per 10 shares (including tax), totaling approximately 510 million yuan, which represents 70.64% of the net profit and a dividend yield of 4.06% based on the average trading price for the year [1][2]. Financial Performance - The company reported a revenue of 3.501 billion yuan for the fiscal year 2024, reflecting a year-on-year growth of 5.72% - The net profit reached 723 million yuan, marking a year-on-year increase of 27.19% - Basic earnings per share were 1.287 yuan, with a weighted average return on equity of 24.8% [2]. Dividend History - The company has a history of consistent dividend payments, with the upcoming distribution being the 23rd since its listing - Previous dividend distributions include: - 2023: 8 yuan per 10 shares, totaling 451 million yuan, with a yield of 5.00% - 2022: 6 yuan per 10 shares, totaling 338 million yuan, with a yield of 4.49% - 2021: 5 yuan per 10 shares, totaling 282 million yuan, with a yield of 4.56% [2]. Market Activity - The stock experienced a net outflow of 10.96 million yuan in principal funds today, with a total outflow of 26.66 million yuan over the past five days [3]. - The latest margin financing balance for the stock is 291 million yuan, with an increase of 5.42 million yuan over the past five days, representing a growth of 1.90% [4]. Industry Comparison - In the pharmaceutical and biotechnology sector, 248 companies have announced their dividend plans for 2024 - Notable companies with higher cash distributions include WuXi AppTec with 7.692 billion yuan, Yunnan Baiyao with 2.114 billion yuan, and Aier Eye Hospital with 1.488 billion yuan [4].